About 2 results found for searched term "NX-2127" (0.08 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43813 | NX-2127 | BTK |
| Zelebrudomide | ||
| Zelebrudomide (NX-2127) is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells. | ||
| M55647 | (R)-NX-2127 | BTK |
| compound 28 | ||
| (R)-NX-2127 (compound 28) is a first-in-class, orally bioavailable Bruton’s Tyrosine Kinase (Btk) degrader. (R)-NX-2127 mediates the degradation of transcription factors IKZF1 and IKZF3 through molecular glue interactions with the cereblon E3 ubiquitin ligase complex. NX-2127 degrades common BTK resistance mutants, including BTKC481S. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
